未分化甲状腺癌新型分子靶向与免疫治疗的研究进展

Research progress of novel molecular target therapy and immunotherapy for anaplastic thyroid cancer

未分化甲状腺癌(ATC)是一种罕见的恶性肿瘤,疾病发展迅速,预后差,目前尚无标准治疗方法,主要采取手术及术后放化疗联合靶向和免疫治疗。肿瘤靶向治疗因其可选择性杀伤肿瘤细胞,延长患者生存时间,不良反应较少,已成为研究热点。免疫治疗主要通过对免疫检查点的抑制,激活自身免疫系统发挥抗肿瘤作用。目前靶向联合免疫治疗在ATC的研究中受到广泛关注,本文对上述相关研究进展进行综述。

Anaplastic thyroid cancer(ATC)is a rare malignant tumor with rapid disease development and poor prognosis.Currently,there is no standard treatment.The established treatment includes surgery with postoperative radiotherapy and chemotherapy,combined with molecularly targeted treatment and immunotherapy.Molecularly targeted treatment has become a research hotspot because it can selectively kill tumor cells,prolong the life time of patients and have fewer adverse effects.Immunotherapy mainly activates the immune system to play an anti-tumor role by inhibiting the immune checkpoint.At present,targeted combined immunotherapy has attracted extensive attention in the study of anaplastic thyroid cancer.This article reviews the relevant research progress.